Table 6

 Summary of outcomes for rimonabant

OutcomeNo of studies (sample size)Weighted mean difference or risk difference (active minus placebo) (95% CI)
Change in weight (kg)4 (4099)−4.67 (−5.26 to −4.07)
5% responders (absolute % difference)4 (4099)0.33* (0.29. 0.37)
10% responders (absolute % difference)4 (4099)0.19* (0.15 to 0.23)
Change in:
 Waist circumference (cm)4 (4098)−3.89 (−4.47 to −3.30)
 Systolic blood pressure (mm Hg)3 (2273)−1.78 (−2.81 to −0.76)
 Diastolic blood pressure (mm Hg)3 (2273)−1.23 (−1.93 to −0.54)
 Total cholesterol (mmol/l)3 (2223)−0.04 (−0.11 to 0.03)
 Low density lipoprotein cholesterol (mmol/l)3 (2223)−0.05 (−0.12 to 0.01)
 High density lipoprotein cholesterol (mmol/l)4 (4050)0.10 (0.08 to 0.11)
 Triglycerides (mmol/l)4 (4049)−0.24 (−0.30 to −0.17)
 Weight in those with diabetes (kg)1 (1047)−3.90 (−4.57 to −3.23)
 Haemoglobin A1C in those with diabetes (%)1 (1047)−0.70 (−0.84 to −0.56)
 Fasting glucose in those with diabetes (mmol/l)1 (1047)−0.97 (−1.30 to −0.64)
Discontinuation because of adverse event (absolute % difference)4 (4105)0.06* (0.05 to 0.08)
Serious adverse event (absolute % difference)4 (4105)0.02* (0.00 to 0.03)
Psychiatric disorders (absolute % difference)4 (4105)0.03* (0.02 to 0.05)

*Risk difference. All other calculations represent weighted mean difference.